Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.71 |
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | NPC1 | O15118 | 8/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | STAT1 | P42224 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121882 | 0.87 | MAPT (0.68) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL4112390 | 0.86 | MAPT (0.58) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL4111961 | 0.86 | CA2 (0.60) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL4346922 | 0.86 | TP53 (0.69) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL22103791 | 0.85 | TSHR (0.82) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL4110798 | 0.85 | NPC1 (0.57) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL4893387 | 0.85 | TP53 (0.87) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL31040569 | 0.85 | TP53 (0.87) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL4346603 | 0.84 | TP53 (0.67) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL4112574 | 0.84 | NPC1 (0.56) | RAB9AMAPTNPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885MAPT 1654/4885NPC1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.